阿帕替尼联合GP方案治疗晚期非小细胞肺癌的疗效及安全性

Efficacy and Safety Analysis of Apatinib Combined with GP Regimen in the Treatment of Advanced Non-small Cell Lung Cancer

目的 探讨阿帕替尼联合GP方案治疗晚期非小细胞肺癌的临床疗效及对肿瘤标志物的影响。方法 选取70例晚期非小细胞肺癌患者作为研究对象,根据随机区组设计法,将所有患者分为观察组和对照组,各35例。对照组采用GP方案治疗,观察组采用阿帕替尼联合GP方案治疗。比较2组患者近期疗效、肿瘤标志物水平、生存情况及毒副作用发生情况。结果 观察组的总缓解率和疾病控制率(57.1%,85.7%)显著高于对照组(28.6%,54.3%)(P<0.05)。观察组血清CEA、VEGF、CYFRA21-1水平显著低于对照组(P<0.05)。观察组SF-36评分、KPS评分显著高于对照组(P<0.05)。观察组中位生存期显著长于对照组(P<0.05),其1年生存率略高于对照组,但无统计学差异(P>0.05)。观察组的白细胞减少、血小板减少、胃肠道反应及肝肾功能损害均显著低于对照组(P<0.05),而心脏毒性无统计学差异(P>0.05)。结论 阿帕替尼联合GP方案可显著提高晚期非小细胞肺癌患者的近期疗效,降低血清肿瘤标志物水平,延长生存期,且并不会明显增加毒副作用。

Objective To investigate the clinical effect of apatinib combined with GP regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its effect on tumor markers. Methods 70 patients with advanced non-small cell lung cancer were selected as the subjects.According to the random area group design method,all the patients were divided into the observation group and the control group,each with 35 cases.The control group was treated with GP regimen.The observation group used apatinib combined with GP regimen.The recent curative effect,the level of tumor markers,the condition of survival and the occurrence of toxic and side effects were compared between the two groups. Results The total remission rate and clinical rate of return in the observation group(57.1%,85.7%) were significantly higher than those of the control group(28.6%,54.3%)( P <0.05).The level of serum CEA,VEGF,CYFRA21-1 in the observation group was significantly lower than that of the control group ( P <0.05).The SF-36 score,KPS score of the observation group was significantly higher than that of the control group ( P <0.05).The median survival time of the observation group was significantly higher than that of the control group ( P <0.05).The 1-year survival rate of the observation group was slightly higher than that of the control group,but there was no statistical difference ( P >0.05).The leucopenia,thrombocytopenia,gastrointestinal reaction and liver and kidney function damage in the observation group were significantly lower than those in the control group ( P <0.05),but there was no significant difference in cardiac toxicity ( P >0.05). Conclusion Apatinib combined with GP regimen can significantly improve the short-term efficacy of advanced non-small cell lung cancer patients,reduce the level of serum tumor markers,prolong the survival period,and do not significantly increase the toxic side effects.